Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
胰腺癌
化疗
危险系数
队列
作者
Theodoros Michelakos,Ilaria Pergolini,Carlos Fernandez-del Castillo,Kim C. Honselmann,Lei Cai,Vikram Deshpande,Jennifer Y. Wo,David P. Ryan,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Janet E. Murphy,Ryan D. Nipp,Aparna Raj Parikh,Motaz Qadan,Andrew L. Warshaw,Theodore S. Hong,Keith D. Lillemoe,Cristina R. Ferrone
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)] 日期:2017-12-01卷期号:269 (4): 733-740被引量:150
标识
DOI:10.1097/sla.0000000000002600
摘要
Objective:The aim of this study was to determine (1) whether preoperative factors can predict resectability of borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant FOLFIRINOX, (2) which patients might benefit from adjuvant therapy, and (3) su